CMS Energy Corp. engages in the provision of electric and natural gas activities. It operates through the following business segments: Electric Utility, Gas Utility, and NorthStar Clean Energy. The Electric Utility segment focuses on generation, purchase, distribution, and sale of electricity. The Gas Utility segment includes purchase, transmission, storage, distribution, and sale of natural gas. The NorthStar Clean Energy segment is involved in domestic independent power production including the development and operation of renewable generation and the marketing of independent power production. The company was founded in 1987 and is headquartered in Jackson, MI.
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
2
66.7%
尚未招募
1
33.3%
暂无批准数据
- CMS Administrator Dr. Oz publicly endorsed FDA approval as the "right way forward" for cannabinoid drug development while his agency simultaneously operates a Medicare program that funds non-FDA-approved hemp-derived cannabinoid products. - The CMS Substance Access Beneficiary Engagement Incentive allows Medicare beneficiaries to receive up to $500 annually in orally administered hemp-derived products containing up to 3 mg THC per serving, without FDA review. - MMJ International Holdings has spent over $10 million and nearly a decade pursuing formal FDA approval for cannabinoid therapeutics targeting Huntington's disease and multiple sclerosis, yet remains without a decision. - The company is appealing a district court dismissal in the D.C. Circuit, arguing the government cannot simultaneously claim the program benefits millions while asserting it is too insignificant to confer legal standing.
- Five Republican members of Congress have urged CMS to reverse a roughly 75% Medicare payment cut for image-guided superficial radiation therapy used in office-based skin cancer treatment. - The payment cut, which took effect January 1, has led more than 160 dermatology practices to discontinue the therapy, potentially pushing rural patients toward less-accessible urban cancer centers. - The dispute highlights an ongoing conflict between dermatologists and radiation oncologists over appropriate use and reimbursement, with CMS and the AMA siding with radiation oncologists. - CMS has stated it remains open to hearing feedback on the effect of final policies for consideration in potential future rulemaking.
- Medicare's mandatory TEAM bundled-payment model for spinal fusion launched January 1, 2026, covering roughly 740 hospitals through 2030 with quality-adjusted reimbursement swings of 10% to 20%. - Outpatient spine volume rose approximately 193% from 2010 to 2021, while the 2026 ASC conversion factor of $56.322 trails hospital outpatient rates of $91.415, intensifying pressure to prove outcomes. - Spine leaders identify data infrastructure—not surgical skill—as the binding constraint, with patient-reported outcome measures, interoperable EHRs, and risk stratification now prerequisites for contract negotiation. - Early adopters of bundled-payment programs report significant growth; OrthoCarolina's program expanded from roughly 80 patients in year one to a projected 2,000-plus in 2026.
- CMS proposes a 2.4% increase to OPPS payment rates for 2027, reflecting a 3.2% market basket update reduced by a 0.8% productivity adjustment. - The rule would slash 340B drug payments to ASP minus 33.4%, aiming to reduce total drug spending by $5.7 billion in 2027. - Site-neutral payments would expand to imaging without contrast at off-campus provider-based departments, saving Medicare approximately $260 million in the first year. - CMS plans to remove approximately half of remaining inpatient-only services, with cardiovascular procedures slated for IPO removal in 2028.
- The DOJ's 2026 National Health Care Fraud Takedown resulted in charges against 455 defendants, including 90 physicians, for schemes involving over $6.5 billion in alleged false claims across 56 federal districts. - Medicaid fraud enforcement reached unprecedented scale with 295 defendants tied to over $518 million in alleged false claims, marking the largest Medicaid fraud action in Takedown history. - Advanced data analytics and AI tools are now central to fraud detection, with CMS deploying predictive algorithms and a multi-agency Data Fusion Center driving investigations. - The Takedown highlighted patient harm cases, including a student athlete death linked to falsified cardiac test results and medically unnecessary wound allograft schemes costing Medicare billions.
- CMS proposed a new rule requiring payers to respond to urgent drug prior authorization requests within 24 hours, expedited within 72 hours, and standard within 7 days, with compliance by October 2027. - An industry pledge led by AHIP reportedly reduced prior authorizations by 11%, but only 33% of physicians surveyed by the AMA believe it will make a meaningful difference. - The American College of Rheumatology supports the CMS rule but urges further detail on denial reasons, specialty-level reporting, and extension to Medicare Part D and state-based exchanges. - A 2025 Commonwealth Fund analysis found 21% of working-age adults with private insurance were denied physician-recommended care, with 41% experiencing delayed care as a result.
- The Department of Health and Human Services announced a coordinated effort across FDA, NIH, CMS, ONC, ARPA-H, and the HHS Office of Inspector General to strengthen America's clinical research enterprise. - China now conducts more early-stage clinical trials than the United States, and Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity in 2025. - FDA estimates that streamlining Phase 1 development and clarifying approval pathways could reduce drug development timelines by 6 to 12 months. - NIH is advancing artificial intelligence, human cell-based models, and real-world data to move promising therapies to patients more efficiently while applying lessons from personalized gene-editing therapies.
- The 2026 Medicare Part A inpatient hospital deductible rose to $1,736 per benefit period, a $60 increase from $1,676 in 2025, and can be charged multiple times in a single calendar year. - The Part B standard monthly premium increased to $202.90 in 2026, a $17.90 jump from $185.00 in 2025, representing the largest dollar increase in years. - The Part D annual out-of-pocket drug spending cap moved to $2,100 in 2026, providing critical protection for beneficiaries on high-cost specialty medications. - CMS attributes the Part B premium increase to projected price changes and utilization trends, partly offset by a 2026 Physician Fee Schedule rule reducing skin-substitute spending.
- PuraPly AM combined with standard care demonstrated statistically significant superiority over standard care alone in treating diabetic foot ulcers in a randomized controlled trial of approximately 170 patients. - The trial achieved wound closure at 12 weeks as a key efficacy endpoint, highlighting the product's therapeutic potential for this challenging patient population. - Organogenesis has completed a Type-B meeting with the FDA and plans to initiate a rolling Biologics License Application for ReNu by the end of December. - Despite positive clinical results, the company faces projected revenue declines of 25-38% in 2026 due to CMS reimbursement changes, though the trial data may help de-risk coverage decisions.
- AbbVie filed a federal lawsuit against HHS challenging the inclusion of Botox in Medicare's drug price negotiation program under the Inflation Reduction Act. - The company argues Botox qualifies for statutory exemption as a plasma-derived product since approximately one-third contains human serum albumin from donated plasma. - AbbVie claims CMS exceeded its authority by selecting Botox for the third cycle of price negotiations set to take effect in 2028. - The lawsuit alleges violations of the Administrative Procedure Act, Fifth Amendment takings clause, and First Amendment compelled speech protections.
